Sivia Capital Partners LLC Reduces Position in AbbVie Inc. (NYSE:ABBV)

Sivia Capital Partners LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 4.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,272 shares of the company’s stock after selling 221 shares during the period. Sivia Capital Partners LLC’s holdings in AbbVie were worth $759,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Quest Partners LLC lifted its holdings in AbbVie by 4,140.0% during the 2nd quarter. Quest Partners LLC now owns 212 shares of the company’s stock valued at $36,000 after buying an additional 207 shares in the last quarter. Jupiter Asset Management Ltd. purchased a new position in AbbVie during the 2nd quarter worth $204,000. GHP Investment Advisors Inc. raised its position in AbbVie by 1.6% during the 2nd quarter. GHP Investment Advisors Inc. now owns 5,801 shares of the company’s stock valued at $995,000 after purchasing an additional 90 shares in the last quarter. Inspire Advisors LLC lifted its holdings in shares of AbbVie by 4.1% in the 2nd quarter. Inspire Advisors LLC now owns 1,537 shares of the company’s stock worth $264,000 after buying an additional 61 shares during the period. Finally, Lyell Wealth Management LP grew its position in shares of AbbVie by 4.0% during the 2nd quarter. Lyell Wealth Management LP now owns 1,671 shares of the company’s stock worth $287,000 after buying an additional 64 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Insider Transactions at AbbVie

In other news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares in the company, valued at $1,202,751.92. The trade was a 20.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.25% of the company’s stock.

AbbVie Price Performance

ABBV traded up $1.83 during trading on Monday, hitting $177.00. The company’s stock had a trading volume of 2,651,849 shares, compared to its average volume of 4,723,911. The firm has a market capitalization of $312.78 billion, a price-to-earnings ratio of 61.46, a P/E/G ratio of 1.92 and a beta of 0.58. AbbVie Inc. has a twelve month low of $153.58 and a twelve month high of $207.32. The business’s fifty day simple moving average is $178.47 and its 200 day simple moving average is $184.55. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.92 by $0.08. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. The company had revenue of $14.46 billion during the quarter, compared to analysts’ expectations of $14.28 billion. During the same period in the prior year, the business posted $2.95 earnings per share. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. On average, equities research analysts forecast that AbbVie Inc. will post 10.96 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be given a $1.64 dividend. This represents a $6.56 annualized dividend and a dividend yield of 3.71%. The ex-dividend date of this dividend is Wednesday, January 15th. This is an increase from AbbVie’s previous quarterly dividend of $1.55. AbbVie’s dividend payout ratio (DPR) is 227.78%.

Analyst Ratings Changes

ABBV has been the subject of a number of research reports. Daiwa America lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 5th. UBS Group boosted their price objective on shares of AbbVie from $195.00 to $200.00 and gave the stock a “neutral” rating in a research note on Thursday, October 31st. Wolfe Research assumed coverage on AbbVie in a research report on Friday, November 15th. They set an “outperform” rating and a $205.00 target price on the stock. Sanford C. Bernstein assumed coverage on AbbVie in a research note on Thursday, October 17th. They set a “market perform” rating and a $203.00 price objective for the company. Finally, Guggenheim lifted their target price on AbbVie from $212.00 to $221.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $205.50.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.